MiR-137 expression in neuroblastoma: a role in clinical course and outcome

• Дата: 2016
• Автори: Inomistova, M.V., Khranovska, N.M., Skachkova, O.V., Klymniuk, G.I., Demydov, S.V., Svergun, N.M.
• Формат: Стаття
• Мова: English
• Опубліковано: Інститут молекулярної біології і генетики НАН України 2016
• Назва видання: Вiopolymers and Cell
• Теми: Biomedicine
• Онлайн доступ: http://dspace.nbuv.gov.ua/handle/123456789/152822
• Назва журналу: Digital Library of Periodicals of National Academy of Sciences of Ukraine
• Цитувати: MiR-137 expression in neuroblastoma: a role in clinical course and outcome / M.V. Inomistova, N.M. Khranovska, O.V. Skachkova, G.I. Klymniuk, S.V. Demydov, N.M. Svergun // Вiopolymers and Cell. — 2016. — Т. 32, № 3. — С. 222-228. — Бібліогр.: 20 назв. — англ.

Aim. To investigate association of the miR-137 expression in neuroblastoma patients with clinical and biological characteristics of the tumor, and the relationship with survival rates. Methods. qRT-PCR, FISH. Results. Analysis of 61 primary diagnosed neuroblastoma samples revealed a significantly lower expression of miR-137 in patients with the higher risk prognostic factors including the MYCN amplification, onset age, disease stage and overexpression of he p53 antagonist MDM2. Although miR-137 is not an independent risk factor, its higher expression was significantly associated with both improved event-free survival (5 year: 50.4 % vs 12.2 %) and overall survival (5 year: 46.9 % vs 19.1 %), indicating a potential tumor suppressor role in neuroblastoma. Conclusion. We identified miR-137 as a new microRNA of potential importance for the neuroblastoma tumor biology. We demonstrated that miR-137 expression can be used as a biomarker to stratify the neuroblastoma patients according to the clinical course.